心肌梗死合并心力衰竭的药物治疗研究进展

摘要/Abstract

摘要： 心力衰竭是心肌梗死患者常见的并发症,与心梗患者的死亡率存在密切的相关性。心肌梗死合并心力衰竭的治疗一直是临床研究的热点和难点。近年来,β受体阻滞剂、血管紧张素转化酶抑制剂（ACEI）、血管紧张素受体拮抗剂（ARB）、盐皮质激素受体拮抗剂（MRAs）、血管紧张素受体-脑啡肽酶抑制剂（ARNI）、钙离子增敏剂及中药制剂在治疗心梗合并心衰患者中显示出了很好的临床疗效,但是仍有许多问题需要解决。本文将对心梗合并心衰的治疗药物研究进展进行综述,为研究者的研究方向和思路提供一定的参考。

关键词: 心肌梗死, 心力衰竭, 药物治疗, 研究进展

刘玉彬. 心肌梗死合并心力衰竭的药物治疗研究进展[J]. 心血管病防治知识, 2023, 13(10): 92-96.

参考文献

[1] Nabel EG, Braunwald E.A tale of coronary artery disease and myocardial infarction[J]. N Engl J Med, 2012,366(1):54-63.
[2] Granger CB, Goldberg RJ, Dabbous O, et al.Predictors of hospital mortality in the global registry of acute coronary events[J]. Arch Intern Med, 2003,163(19):2345-2353.
[3] Bahit MC, Kochar A, Granger CB.Post-Myocardial Infarction Heart Failure[J]. JACC Heart Fail, 2018,6(3):179-186.
[4] Ponikowski P, Voors AA, Anker SD, et al.2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure[J]. Rev Esp Cardiol (Engl Ed), 2016,69(12):1167.
[5] Coiro S, Girerd N, Rossignol P, et al.Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the High-Risk Myocardial Infarction Database Initiative[J]. Clin Res Cardiol, 2017,106(9):722-733.
[6] Bayram M, De Luca L, Massie MB, et al.Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes[J]. Am J Cardiol, 2005,96(6A):47G-58G.
[7] 宋锴铖, 周立君. 急性心肌梗死合并心源性休克的临床诊断及治疗进展[J]. 心血管病学进展, 2017,38(5):543-548.
[8] Teerlink JR, Diaz R, Felker GM, et al.Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure[J]. N Engl J Med, 2021,384(2):105-116.
[9] Kim J, Kang D, Park H, et al.Long-term β-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study[J]. Eur Heart J, 2020,41(37):3521-3529.
[10] Neumann A, Maura G, Weill A, et al.Clinical Events After Discontinuation of β-Blockers in Patients Without Heart Failure Optimally Treated After Acute Myocardial Infarction: A Cohort Study on the French Healthcare Databases[J]. Circ Cardiovasc Qual Outcomes, 2018,11(4):e004356.
[11] Dargie HJ.Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial[J]. Lancet, 2001,357(9266):1385-1390.
[12] Song PS, Kim M, Seong SW, et al.Heart failure with mid-range ejection fraction and the effect of β-blockers after acute myocardial infarction[J]. Heart Vessels, 2021,36(12):1848-1855.
[13] Chen ZM, Pan HC, Chen YP, et al.Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial[J]. Lancet, 2005,366(9497):1622-1632.
[14] Pfeffer MA, Braunwald E, Moyé LA, et al.Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators[J]. N Engl J Med, 1992,327(10):669-677.
[15] Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators[J]. Lancet, 1993,342(8875):821-828.
[16] Torp-Pedersen C, Kober L.Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation[J]. Lancet, 1999,354(9172):9-12.
[17] Wu J, Hall AS, Gale CP.Long-term survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure[J]. Heart, 2021,107(5):389-395.
[18] Dickstein K, Kjekshus J.Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan[J]. Lancet, 2002,360(9335):752-760.
[19] Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both[J]. N Engl J Med, 2003,349(20):1893-906.
[20] Pitt B, Zannad F, Remme WJ, et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators[J]. N Engl J Med, 1999,341(10):709-717.
[21] Pitt B, Remme W, Zannad F, et al.Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction[J]. N Engl J Med, 2003,348(14):1309-1321.
[22] Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms[J]. N Engl J Med, 2011,364(1):11-21.
[23] Stienen S, Rossignol P, Barros A, et al.Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials[J]. Clin Res Cardiol, 2020,109(2):194-204.
[24] Stienen S, Ferreira JP, Pitt B, et al.Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure[J]. Eur J Heart Fail, 2020,22(5):901-903.
[25] Martens P, Ferreira JP, Vincent J, et al.Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHESUS trial[J]. Clin Res Cardiol, 2021.
[26] Braunwald E.The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure[J]. J Am Coll Cardiol, 2015,65(10):1029-1041.
[27] McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014,371(11):993-1004.
[28] De Luca L.Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence[J]. Cardiovasc Drugs Ther, 2020,34(5):723-735.
[29] 吴会文, 杨丽文. 沙库巴曲缬沙坦治疗急性心肌梗死后严重心力衰竭的疗效分析[J]. 中西医结合心血管病电子杂志, 2020,24:71.
[30] Fang J, Zeng W.A meta-analysis of the clinical efficacy of rhBNP in treating patients with acute myocardial infarction and heart failure[J]. Am J Transl Res, 2021,13(4):2410-2421.
[31] He XM, Chen L, Luo JB, et al.Effects of rhBNP after PCI on non-invasive hemodynamic in acute myocardial infarction patients with left heart failure[J]. Asian Pac J Trop Med, 2016,9(8):791-795.
[32] Xu H, Wang B, Meng Q, et al.Effectiveness and safety of recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction in elderly in combination with cardiac failure[J]. Pak J Med Sci, 2017,33(3):540-544.
[33] Cholley B, Levy B, Fellahi JL, et al.Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper[J]. Crit Care, 2019,23(1):385.
[34] Moiseyev VS, Poder P, Andrejevs N, et al.Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)[J]. Eur Heart J, 2002,23(18):1422-1432.
[35] Husebye T, Eritsland J, Müller C, et al.Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study[J]. Eur J Heart Fail, 2013,15(5):565-572.
[36] Li Y, Zhang Z, Li S, et al.Therapeutic Effects of Traditional Chinese Medicine on Cardiovascular Diseases: the Central Role of Calcium Signaling[J]. Front Pharmacol, 2021,12:682273.
[37] 叶丽莎, 白雪, 张德绸. 心安颗粒对急性心肌梗死后心衰患者心功能的影响研究[J]. 中国处方药, 2020,10:85-86.
[38] 陈运起, 史丽. 黄芪保心颗粒对急性心肌梗死伴心衰患者左心功能及血清H-FABP、cTnⅠ、Nt-proBNP的影响[J]. 中药药理与临床, 2017,4:190-193.
[39] Zhang Y, Li C, Meng H, et al.BYD Ameliorates Oxidative Stress-Induced Myocardial Apoptosis in Heart Failure Post-Acute Myocardial Infarction via the P38 MAPK-CRYAB Signaling Pathway[J]. Front Physiol, 2018,9:505.
[40] Zhu Y, Zhao J, Han Q, et al.The Effect and Mechanism of Chinese Herbal Formula Sini Tang in Heart Failure after Myocardial Infarction in Rats[J]. Evid Based Complement Alternat Med, 2018:5629342.
[41] Wang Y, Fu M, Wang J, et al.Qiliqiangxin Improves Cardiac Function through Regulating Energy Metabolism via HIF-1α-Dependent and Independent Mechanisms in Heart Failure Rats after Acute Myocardial Infarction[J]. Biomed Res Int, 2020:1276195.